Mild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequences by Wortmann, SB et al.
ORIGINAL ARTICLE
Mild orotic aciduria in UMPS heterozygotes: a metabolic finding
without clinical consequences
Saskia B. Wortmann1,2,3 & Margaret A. Chen4 & Roberto Colombo5 &
Alessandro Pontoglio6 & Bader Alhaddad3 & Lorenzo D. Botto7 & Tatiana Yuzyuk8,9 &
Curtis R. Coughlin10 & Maria Descartes11 & Stephanie Grűnewald12 & Bruno Maranda13 &
Philippa B. Mills14 & James Pitt15,16 & Catherine Potente17 & Richard Rodenburg18 &
Leo A. J. Kluijtmans18 & Srirangan Sampath4 & Emil F. Pai19 & Ron A. Wevers18 &
George E. Tiller20 & and additional individual contributors
Received: 5 December 2016 /Revised: 5 January 2017 /Accepted: 9 January 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Background Elevated urinary excretion of orotic acid is asso-
ciated with treatable disorders of the urea cycle and pyrimidine
metabolism. Establishing the correct and timely diagnosis in a
patient with orotic aciduria is key to effective treatment. Uridine
monophosphate synthase is involved in de novo pyrimidine
synthesis. Uridine monophosphate synthase deficiency (or he-
reditary orotic aciduria), due to biallelic mutations in UMPS, is
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a rare condition presenting with megaloblastic anemia in the
first months of life. If not treated with the pyrimidine precursor
uridine, neutropenia, failure to thrive, growth retardation, devel-
opmental delay, and intellectual disability may ensue.
Methods and results We identified mild and isolated orotic
aciduria in 11 unrelated individuals with diverse clinical signs
and symptoms, themost common denominator being intellectual
disability/developmental delay. Of note, none had blood count
abnormalities, relevant hyperammonemia or altered plasma ami-
no acid profile. All individuals were found to have heterozygous
alterations in UMPS. Four of these variants were predicted to be
null alleles with complete loss of function. The remaining vari-
ants were missense changes and predicted to be damaging to the
normal encoded protein. Interestingly, family screening revealed
heterozygous UMPS variants in combination with mild orotic
aciduria in 19 clinically asymptomatic family members.
Conclusions We therefore conclude that heterozygous
UMPS-mutations can lead to mild and isolated orotic aciduria
without clinical consequence. Partial UMPS-deficiency
should be included in the differential diagnosis of mild orotic
aciduria. The discovery of heterozygotes manifesting clinical
symptoms such as hypotonia and developmental delay are
likely due to ascertainment bias.
Abbreviations
OA Orotic aciduria
OTC Ornithine transcarbamylase
UMPS Uridine monophosphate synthase
OPRTase Orotate phosphoribosyltransferase
OMPdecase Orotidine decarboxylase
Introduction
Establishing the correct and timely diagnosis in a patient with
elevated urinary excretion of orotic acid is key to effective
treatment. The differential diagnosis of orotic aciduria (OA)
is broad, and includes several treatable disorders, like urea
cycle defects (especially ornithine transcarbamylase (OTC)
deficiency) and uridine monophosphate synthase (UMPS) de-
ficiency (Lichter-Konecki et al 2016). Additionally, OA can
be seen in mitochondrial disorders, lysinuric protein intoler-
ance, liver disease, and has been reported in Rett syndrome,
malignancies, as a side effect of certain medications and in
trauma victims (Jeevanandam et al 1991).
UMPS-deficiency (or hereditary OA,MIM#258900) is a rare
inborn error of metabolism (reviewed in Balasubramaniam et al
2014). UMPS (EC 4.1.1.23), encoded by the UMPS gene, is a
bifunctional protein in the de novo pyrimidine synthesis. In the
first reaction, orotate phosphoribosyltransferase (OPRTase) con-
verts orotate to orotidine monophosphate. In the second step,
orotidine decarboxylase (OMPdecase) decarboxylates orotidine
monophosphate to uridine monophosphate. Patients with
UMPS-deficiency reported to date presented with megaloblastic
anemia in the first months of life. If untreated this disorder can
lead to neutropenia, failure to thrive, growth retardation, sparse
hair and nail growth, developmental delay, intellectual disability,
and epilepsy. Gross excretion of orotic acid may also cause
crystalluria in later life (Bailey 2009; Grohmann et al 2015).
The UMPS gene consists of six exons, and encodes a pro-
tein that is 480 amino acids in length (Suchi et al 1997). In
mammals and yeast, the active enzyme is a dimer (Wittmann
et al 2008). The first N-terminal 214 amino acids comprise
OPRTase, while the C-terminal 258 amino acids comprise
OMPdecase (Suttle et al 1988). Biallelic missense mutations
which lead to amino acid substitutions are a presumed com-
mon cause of disease; biochemical studies in cell lines from
UMPS-deficient patients have demonstrated decreased
steady-state levels of the enzyme, impaired substrate binding,
and reduced catalytic efficiency (Winkler and Suttle 1988;
Perry and Jones 1989; Suchi et al 1997).
Here we discuss the clinical relevance of heterozygosity for
UMPS variants and mild OA by presenting a case series of 11
index cases and 18 healthy family members.
Individuals and methods
Metabolic screening included complete blood count, blood gas
analysis, serum glucose, electrolytes and lactate, plasma ammo-
nia and amino acids, urinary organic acids, purines and pyrimi-
dines and was (repetitively) performed using standard methods.
Enzyme activity in erythrocytes OPRTase and
OMPdecase activities were determined in lysates of fresh
erythrocytes as previously described (Krungkrai et al 2001)
Genetic investigations Exome sequencing of the individuals
III-6, III-7, IV-5, and IV-6 from pedigree 2, I8, I10, and I11
was performed as previously described (Wortmann et al
2015). Bidirectional Sanger sequencing of all six UMPS
(NM_000373.3 (hg19)) coding exons plus ∼20 bp of flanking
non-coding intronic DNAwas performed in individuals I2-I11
and family members on genomic DNA using standard
methods (primer sequences and PCR conditions are available
upon request). SNP array analysis (Affymetrix SNP 6.0) of
individuals I1, I4, and I8 as well as karyotyping of I4 was
performed by standard methods. Whole genome copy number
screening was also performed for individual I8 (CytoSure
ISCAv2 4x180k array, Oxford Gene Technology). Gene-spe-
cific deletion/duplication testing of UMPS of individuals I4,
I6, and I7 was performed via high density gene-centric array
CGH (Prevention Genetics, details available upon request).
Gene panel sequencing (GPS) of individual I12 was per-
formed using a targeted panel of genes causing inborn errors
of metabolism (details available upon request).
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Molecularmodeling of UMPS variantsThemodels present-
ed are based on PDB-entries 2WNS and 3BGG (www.rcsb.
org/pdb/) for the OPRTase and OMPdecase domains of
human UMPS, respectively. Figure 2 was prepared using
PyMOL 1.6.0.0 (The PyMOL Molecular Graphics System,
Version 1.8 Schrödinger, LLC).
Clinical cohort
The 11 index individuals (I1….I13) were referred for various
signs and symptoms as detailed below; all were shown to have
OA (summarized in Table 1). Additionally, one pedigree (Ped2)
is described in which the index case did not have OA, but
several familymembers. Of note, none of the investigated index
patients nor their family members had relevant anemia or neu-
tropenia, hyperammonemia, growth delay or failure to thrive.
Individual I1, an Australian female born at term, presented
neonatally with a clinical picture of encephalitis. Metabolic
screening showed mild transient hyperammonemia and per-
sistent OA without any other biochemical abnormalities.
Apneic episodes resolved over 5 days and she was discharged
on day 9. Brain MRI showed isolated partial agenesis of the
corpus callosum. She had feeding difficulties as an infant and
dysplastic hips. Repetitive metabolic screening showed no
Table 1 Clinical and metabolic findings and UMPS carrier status of all individuals
UMPS
mutation
Clinical signs and symptoms Urinary orotic acid
(umol/mmol creatinine)
Max. factor of urinary
orotic acid elevation
Orotate/
orotidine ratio
I1 + Neonatal encephalitis, feeding difficulties, mild LD 30, 31 (RR<4.9) 6.3 n/a
M1, F1 – NRMC n/a n/a
Ped2 + 12 x NRMC 22–43.1 (RR 0.05–3) 14.3 n/a
Ped2 – 13 x NRMC, 1x ID/DD, infantile seizures <0.2–3 (RR 0.05–3)
I3 + ID 10.5 (RR <1.5 +/−0.4) 5.3 n/a
M3 + n/a 38 (RR 4.9 +/−1.8) 5.7 n/a
I4 + DD, myoclonic seizures 17.3 (RR 1–3.2) 5.4 13.5
I5 + Mild LD 15.5–49 (RR <1.5) 6 (after allopurinol 32.3) 5–15.2
M5 + NRMC 7.3 (RR <1.5) 5 n/a
F5 – NRMC Unmeasurably low n/a
I6 + FTT, speech delay 34–53 (RR <4.9) 10.8 6.4
M6 + mild ID 13.8 (RR <4.9) 2.8 n/a
S6 – NRMC <4.9 (RR <4.9)
I7 + DD, dysmorphic features, hypotonia 40 (RR <8) 5 3.36
F7 – NRMC n/a n/a
M7 + NRMC n/a n/a
S7 + NRMC 7.8 (RR <3.4) 2.32 n/a
I8 + DD, joint hypermobility 7–16, after allopurinol
44–182 (RR <4)
4 (after allopurinol 45) 1.6–7.3
M8 + NRMC 4 (RR <4) – 5
I9 + DD 18–35 (RR <7) 5 n/a
I10 + DD, hypotonia, joint hypermobility, exercise intolerance 14–23 (RR <4) 5.75 5.4–8.5
M10 + NRMC 19 (RR <4) 4.75 n/a
F10 – NRMC <4 (RR <4) – n/a
I11 + diabetes mellitus I, autism, Mauriac syndrome 11 (RR <4) 2.75 8.5
M11 – NRMC <2 (RR <4) – n/a
F11 + NRMC 10 (RR <4) 2.5 3.4
I12 + NRMC 9, 11, 11, 24, 16, 28,
42, 48, 39, 40, 44,
34 (RR <5)
9.6 n/a
M12 n/a NRMC <5 (RR <5) n/a
F12 n/a NRMC <5 (RR <5) n/a
DD developmental delay, F father of, FTT failure to thrive, I individual, ID intellectual disability, LD learning disability,Mmother of, n/a not available,
NRMC no relevant medical complaints, Ped pedigree, RR reference range, S sibling of
*in pedigree 2 26 family members were tested (see Fig. 1 for individual values)
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abnormalities other than consistent isolated OA. Currently, at
the age of 6 years, she has some learning difficulties and is
educated in a mainstream school with additional support. Both
parents (M1, F1) had no relevant medical complaints
(NRMC); urine of parents was not tested. Pedigree P2
(Fig. 1a): The parents of this Bindex^ male (IV:6) with intel-
lectual disability and infantile seizures were seeking genetic
advice. They agreed to participate in a study for establishing
reference values for urinary purines and pyrimidines measure-
ments. This lead to detection of OA in the Italian father (III:6)
and the older brother (IV:5) of this Bindex^ who both had
NRMC. The Bindex^ himself and his Croatian mother (III:7)
did not show OA. OPRTase activities were within the normal
range for all four familymembers (father 0.037 ± 0.008, moth-
er 0.312 ± 0.087, older son 0.265 ± 0.079, Bindex^ 0.059 ±
0.008; reference range 0.288 ± 0.073 nmol/mg protein/h).
OMPdecase activities were in the heterozygous range in the
father (0.073 ± 0.011) and older son (0.096 ± 0.008), and
normal in the mother (0.395 ± 0.091) and the Bindex^
(0.424 ± 0.098; reference range 0.409 ± 0.094 nmol/mg pro-
tein/h). Finally, a total of 12 family members were shown to
have OA and another 14 did not have OA. Beside the Bindex^
(without OA), NRMC were reported for the other family
members. Individual I3 (data extracted from Suchi et al
1997; Imaeda et al 1998), a Japanese male of unreported
age, was evaluated for intellectual disability. He and his
healthy mother (M3) were both reported to have OA. In both
individuals, the OPRTase and OMPdecase enzymes measured
in red blood cells were reported to be reduced but in the het-
erozygous range (details not given). No details of the father
were provided. Individual I4 presented at the age of 7 months
with developmental delay. At the age of 16 months, this
Caucasian male had his first myoclonic seizures; a brain
MRI at the same age was unremarkable. Mild OAwas noted,
but further metabolic screening was unremarkable. Both par-
ents (M4, F4) had NRMC. Individual I5, a 6 year old
Fig. 1 Pedigree of family P2 and structure of the human UMPS gene
including variants described in all individuals. a Half-filled symbols in-
dicate ascertained orotic aciduria heterozygous subjects. An asterisk (*)
denotes the Bindex^ case. Carrier status for UMPS p.Pro75His mutation
(genotype C/A at UMPS c.224 locus) is reported under the symbols,
followed by the level of urinary orotic acid (μmol/mmol creatinine; ref-
erence range: 0.05–3). b Structure of the human UMPS gene including
variants described in all individuals. OMPdecase orotidine decarboxyl-
ase, OPRTase orotate phosphoribosyltransferase
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Hispanic male, presented as a premature infant (30 weeks of
gestation) with transient hyperammonemia. Urine organic ac-
id profile revealed persistent mild OA. Development has been
normal, except for a mild learning disability (WISC-V: aver-
age global IQ, lower score for working memory and risc score
for inattention/impulsivity). His mother (M5) also showed
mild OA, but his father (F5) did not. Both parents had
NRMC. Individual I6, a 20 month old Caucasian male, pre-
sented with failure to thrive, multiple food allergies, and
speech delay. Metabolic screening was unremarkable except
for persistent OA. The mother (M6) has mild cognitive im-
pairment and a moderate degree of OA; a healthy male ma-
ternal half-sibling (S6) did not exhibit OA. The father was not
available for evaluation. Individual I7, a 10 month old
Caucasian male, presented with dysmorphic features, hypoto-
nia, developmental delay, and macrocephaly. Past medical
history was notable for resuscitation at birth after an unre-
markable pregnancy. His history further included strabismus,
dysphagia, gastroesophageal reflux, and recurrent abdominal
pain, as well as left talipes equinovarus. Urinary organic acid
analysis revealed repeatedly mild OA, once with concomitant
slightly elevations of glycolic acid, oxalic acid and uracil.
Urinary purine and pyrimidine analysis was initially normal,
however, repeated testing showed an elevated orotic acid. At
3 years of age the patient was healthy and making develop-
mental gains. The patient’s healthy brother (S7) also showed
mild OA. Neither parent (M7, F7) had any relevant medical
complaints. Individual I8, a 1 year old Dutch female, present-
ed with global developmental delay, generalized joint hyper-
mobility and persistent OA. Over time, her development
showed a satisfactory catch-up development, and at 5 years
of age she is attending regular school. She still has joint hy-
permobility. The mother (M8) had NRMC and no OA. The
biological father was an anonymous sperm donor. Individual
I9 2.5 year old French-Canadian female, presented with glob-
al developmental delay. Her past medical history was other-
wise unremarkable. The metabolic screening was consistently
normal with exception of OA. The family history was unre-
markable and parents (M9, F9) had NRMC. Individual I10, a
1 year old Dutch male, presented with generalized muscular
hypotonia, joint hypermobility, and weakness of the ocular,
oral, and limb girdle musculature. A muscle biopsy showed
fiber type disproportion. Metabolic screening revealed isolat-
ed OA with no other abnormalities. At last evaluation (age
7 years), he showed an increase in muscle strength and im-
provedmotor development. The parents are healthy, the moth-
er (M10) exhibited mild OA; urine analysis of the father (F10)
was unremarkable. Individual I11, a 16 year old Dutch male
with autism and poorly controlled type I diabetes mellitus,
presented with liver failure. Elevated transaminases and lac-
tate levels were evident on admission. The diagnosis of
Mauriac syndrome (secondary hepatic glycogenosis in poorly
controlled diabetes mellitus type I) was made and he fully
recovered with improved diabetes control. Metabolic screen-
ing showed isolated OA. Both parents are healthy, the father
(F11) exhibited mild OA; urine analysis of the mother (M11)
was unremarkable.
Individual I12, the second child of healthy unrelated
Polish parents, was brought to attention at birth. His older
brother was born prematurely and died neonatally due to
hyperammonaemia of unknown cause. This sibling was treat-
ed prospectively from birth with a low protein diet, sodium
benzoate, and arginine supplements. There were no clinical
concerns regarding this child, however urinary organic acid
analysis showed persistent mild OA. Around 6 months of age
his diet was liberalized and medication was ceased. At last
evaluation (age 3 years) he was neuro-developmentally nor-
mal. Both parents (M12, F 12) have normal urine organic
acids and NRMC.
Results
Genetic results (Table 2, Figs. 1 and 2)
SNP array of I1 showed a de novo 6.4 Mb deletion on
chromosome 3 (chr3:121233326–127618464) containing
more than 40 RefSeq genes, including UMPS, making it likely
to be contributing to the patient’s phenotype. It did not contain
any genes known to cause agenesis of the corpus callosum
when deleted. In four individuals (I4, I7, I10, I11) and four
healthy family members (M7, S7, M10, F11), three different
heterozygous alterations UMPS were found which were pre-
dicted to lead to a premature stop and thereby loss of normal
protein function via protein truncation or nonsense-mediated
mRNA decay (NMD). In I4 c.302delA (p.Lys101Argfs*9)
was found; karyotyping, SNP array, and gene-specific
deletion/duplication testing of UMPS via high-density gene-
centric array CGH did not reveal abnormalities. No family
members were tested. I7 harbored the c.385G>T (p.Gly129*)
variant in UMPS, which was maternally inherited and also
found in the healthy brother (S7). In both I10 and I11 (coming
from the same region of the Netherlands), a c.889G>T
(p.Glu297*) variant was found (maternally inherited in I10;
paternally in I11). In six individuals (I3, I5, I6, I8, I9, I12)
and 16 healthy familymembers (M3,M5,M6,M7, n = 12 from
pedigree 2) seven different heterozygous missense alterations
were detected. In pedigree 2, 12 family members (Fig. 1) tested
positive for the c.224C>A (p.Pro75His) variant. In five cases
the variant was derived maternally, in four cases paternally and
in three cases it is unknown. In I3 and his healthy mother M3
(7,13) two variants c.286A>G (p.Arg96Gly) and c.1285G>C
(p.Gly429Arg) in UMPS were found, therefore likely to be on
the same allele. In I5 the variant c.310G>A (Gly104Arg) was
detected, I6 harbored c.689G>A (p.Arg230His), in I7
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c.688C>T (p.Arg230Cys) was found, both were maternally
inherited. In I9 c.857T>A (p.Ile286Asn) and in I11
c.451G>A (p.Val151Met) were detected; both parents were
not tested. The missense alterations found were predicted to
be pathogenic by different software programs (PolyPhen-2,
SIFT, MutationTaster). All amino acids affected were well-
conserved from H. sapiens (down) to D. melanogaster or to
C. elegans. I6 was also heterozygous for a second maternally
inherited undocumented variant, c.360A>G (p.Leu120Leu), a
synonymous change. In individuals 4, 6, and 7, additionally
copy number variations in UMPS were excluded. Most of the
variants were not listed in the Exac browser; for those listed, the
allele frequencies were below 0.001 (Table 2).
Molecular modeling of UMPS variants The effects of mis-
sense mutations in the UMPS gene on the protein conforma-
tion are illustrated in Fig. 2 and described in the legend of the
figure.
Discussion
Establishing the correct and timely diagnosis in a patient with
OA is key to effective treatment. The more common ureaTa
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Fig. 2 Molecular modeling of UMPS missense variants. a Arg96Gly:
Arg96 binds to Glu134, which is part of a short helix and in close
proximity to Ser131 that binds to the OMP 5′-phosphate (OMP) substrate.
The same serine residue also interacts tightly with Lys29, which in turn
binds to OMP. Mutation of Arg96 to Gly destroys the interaction with
Glu134, with potential effects on helix placement and substrate-enzyme
contacts. bGly104Arg:Gly104 is part of a ß-turn located at the surface of
the protein molecule. The side chain of the substituted arginine would
point into the solvent with no obvious major direct structural effects.
However, it is possible that the ß-turn could become destabilized, with
potential consequences for folding and stability of the protein molecule. c
Val151Met: Replacing the short side chain of Val151 with a bulky me-
thionine would lead to a large number of contacts shorter than the sum of
van der Waals radii between residues of the hydrophobic cluster sur-
rounding this residue with obvious effects on the stability of the protein
fold and side chain orientation. One member of the hydrophobic cluster is
Val126, which is right next to the substrate OMP; any shift away from
valine’s present position would interfere with substrate binding. d
Arg230: Arg230 is on the surface of the protein molecule, but its side
chain points into the body of the protein and participates in a large number
of electrostatic and hydrogen-bonding interactions. e Arg230His:
Substituting Arg230 (an important anchor point for several secondary
structure elements) with His would lead to a loss of all these interactions.
f Arg230Cys: As indicated in Fig. 2e for the Arg230His mutation, re-
placing the long charged side chain of Arg230 (see Fig. 2d) with themuch
smaller Cys leads to the same loss of interactions. g Ile286Asn:
Introducing an asparagine residue at this position places a polar side chain
close enough to neighboring His283 to make hydrogen bonding a possi-
bility. The subsequent rotation of the His283 ring could destroy binding
of His283 to the ribose moiety in OMP. h Gly429Arg:Gly429 is located
on the dimer interface of the protein, as well as part of a loop surrounding
the orotidine moiety of OMP (Wittmann et al., 2008). The substitution of
arginine at this residue could interfere with dimerization, and possibly
impact substrate binding by Gln241
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cycle disorders require a protein-restricted diet, prevention of
catabolic situations, and treatment with ammonia-
detoxificating medication (Lichter-Konecki et al 2016). The
very rare UMPS-deficiency has been treated successfully with
uridine compounds (Becroft and Phillips 1965; Alvarado et al
1988; Bensen et al 1991). In addition, the correct diagnosis
has a substantial impact on the counseling of the patient and
the family, including discussion of recurrence risk.
The literature does not provide us with a reliable estimate
of the incidence of OA due to UMPS-deficiency nor the prev-
alence of UMPS-mutation carriers. A single survey (Rogers
et al 1975) described the results of screening over 1000
Bmentally retarded^ patients for organic acidurias. Of nine
subjects with OA, two were found to have decreased
OPRTase and OMPdecase enzyme activities, which were also
documented in a parent of each child. Early reports of children
with OAwithout megaloblastic anemia, abnormal growth, or
developmental delay (Tubergen et al 1969) maywell represent
UMPS-mutation carriers, as they were reported in the pre-
molecular age.
Due to lack of clinical information, present-day databases
do not shed light on the incidence of OA either. There are over
70 entries in the ClinVar/dbVar databases with genomic dele-
tions that include UMPS, but only seven are described as
Bpathogenic.^ Those deletions range from 4 to 94 Mb in size,
and include from 45 to 707 genes. No clinical or biochemical
information is available. There are 48 missense variants listed
in Ensembl for which additional information is available, but
only the three mutations reported by (Suchi et al 1997) were
identified as pathogenic. These three mutations are also the
only pathogenic mutations among the 150 missense variants
listed in the ExAC browser as well as the 155 missense vari-
ants listed in dbSNP. Since many of the variants listed may be
benign, it is clear that these databases are failing to support
clinicians.
As demonstrated in the 11 individuals described, OA is a
prominent and challenging biomarker that can mislead the
diagnostic team of metabolic physicians and laboratory staff,
potentially delay arrival at the correct diagnosis, increase di-
agnostic costs, and generate unpleasant and often unnecessary
investigations in children (e.g., repetitive ammonia and OA
testing, allopurinol loading test in I8, OTC gene sequencing
etc.). The individuals reported herein all had urinary OA levels
(elevated 2.5–14.3 times of upper reference limit) that were
relatively constant unlike in OTC deficiency, in which levels
vary greatly (Lichter-Konecki et al 2016) and are usually
much lower than in class ical UMPS-def ic iency.
Furthermore, the individuals in our cohort had non-
informative plasma amino acid profiles and no other abnormal
laboratory findings, especially no relevant hyperammonemia
nor hematological abnormalities. TheUMPS-mutations found
in these individuals occurred in both domains of the enzyme
(OPRTase and OMPdecase). Mutations in both parts of the
enzyme led to similar mildly increased urinary orotic acid
concentrations.
Metabolic screening in the individuals described (Table 1)
was pursued most often due to delayed development (n = 6),
which is a common practice (van Karnebeek et al 2014). Other
indications were muscular hypotonia, suspicion of a mito-
chondrial disorder, neonatal encephalitis, liver failure, and un-
explained neonatal death of a sibling with hyperammonemia.
In all cases the clinical signs and symptoms were non-specific
and together with the metabolic screening results were not
suggestive of a known disorder associated with OA.
Additionally, OAwas also present in 18 family members har-
boring the same genetic variants as the probands. Only one
carrier parent (M8) did not exhibit OA.
A previous study identified several individuals with be-
nign, persistent OA and heterozygosity for an UMPS defect
was suggested as one of several possible reasons for these
observations (Carpenter et al 1997). Our findings confirm that
heterozygous alterations inUMPS can indeed lead to mild and
isolated OAwithout clinical consequences.
Balasubramaniam et al (2014) suggested that calculation of
the orotate/orotidine ratio may reflect the effect of mutations
on the relative activities of ORPTase and OMPdecase. We did
not see a correlation in this ratio in our series of patients.
Urinary orotidine levels were available in six patients in our
cohort. Four of these patients harbored mutations leading to
premature termination of translation, which should impact
both enzymatic activities. The other two patients harbored
different missense mutations in the same codon (230) of
UMPS (which lies in the OMPdecase coding region). These
are predicted to interfere with electrostatic interactions within
the OMPdecase region but not necessarily alter dimerization.
There were overlapping orotate/orotidine ratios between these
two groups of patients, hence precluding any biochemical
correlation.
Therefore, we conclude that heterozygous alterations in
UMPS can lead to mild and isolated OAwithout clinical conse-
quences. The prevalent presentation of developmental delay in
our patient populationmay be due to ascertainment bias. Five (I3,
I4, I5, I7, I8, I10) of six individuals with some degree of devel-
opmental delay or intellectual disability had maternally derived
mutations. This may suggest that in utero exposure to elevated
levels of orotic acid and/or decreased pools of pyrimidines may
impact neurologic development. This theory, however, is not
corroborated by the fact that the siblings S6 and S7, as well as
five individuals from pedigree 2, with maternally derived muta-
tions do not have any relevant medical complaints.
In summary, heterozygous rare variants in UMPS should
be considered in all patients with isolated mild OA before
pursuing further diagnostic studies. Alternatively, measur-
ing urinary orotic acid levels in parents is a rapid and inex-
pensive means of determining clinical significance of OA
in children.
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